The following questions provide general scientific and product information about Sermaglutide and the analytical documentation associated with Whitey’s Peps research materials.
Semaglutide is a peptide that activates the glucagon-like peptide-1 (GLP-1) receptor.
Semaglutide has been studied extensively for its effects on body weight, glucose regulation, appetite, and other metabolic measures. Clinical research has evaluated these effects in adults with obesity, overweight, and type 2 diabetes.
Semaglutide activates the GLP-1 receptor. Research has examined how GLP-1 receptor signaling may influence glucose regulation, insulin secretion, appetite, gastric emptying, energy balance, and body weight.
In the 68-week STEP 1 trial, mean body-weight change was −14.9% with semaglutide compared with −2.4% with placebo. Results varied according to the study population, treatment period, and other study factors.
Clinical studies have examined changes in waist circumference, glycemic measures, blood pressure, lipid measures, and other cardiometabolic endpoints.
Where applicable, independent laboratory documentation may provide information about product identity, purity, and other analytical characteristics of a tested batch. Analytical results apply only to the specific sample or batch identified in the applicable laboratory documentation.